Can-Fite BioPharma Ltd (CANF) has released an update.
Can-Fite BioPharma Ltd. convened a conference with 75 oncologists and coordinators to expedite patient enrollment in their Phase 3 trial for an advanced liver cancer drug, Namodenoson. The drug has received regulatory endorsement from the FDA and EMA, and holds Orphan Drug and Fast Track status for hepatocellular carcinoma (HCC) treatment. With liver cancer causing over 700,000 deaths annually, Namodenoson’s progress is keenly anticipated in a market projected to hit $6.1 billion by 2027 for G8 countries.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
